IP Library Granted Patent US 8,883,499
Granted Patent B2
US 8,883,499 · App. 13/452,349 · Granted Nov 11, 2014

Systems and methods for isolating and using clinically safe adipose derived regenerative cells

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,883,499
App. No.
13/452,349
Granted
Nov 11, 2014
Kind
B2
Abstract

Systems and methods are described that are used to separate cells from a wide variety of tissues. In particular, automated systems and methods are described that separate regenerative cells, e.g., stem and/or progenitor cells, from adipose tissue. The systems and methods described herein provide rapid and reliable methods of separating and concentrating regenerative cells suitable for re-infusion into a subject.

Claims (37)

1. An automated cell processing unit for isolating a concentrated cell population comprising CD31 positive cells from adipose tissue, wherein said cell processing unit is configured to maintain a closed system, comprising:

a tissue collection chamber that is configured to receive a first portion of unprocessed adipose tissue from said subject while maintaining a closed system, wherein said tissue collection chamber comprises an aspiration port;

a first filter that is disposed within said tissue collection chamber, wherein said first filter is configured to substantially retain a first component of said unprocessed adipose tissue and substantially pass a second component of said unprocessed adipose tissue, such that said first filter substantially separates said first component from said second component, and wherein said first component comprises a cell population that comprises adipose-derived stem cells and said second component comprises lipid, blood, mature adipocytes and washing solution;

a processing chamber that is joined to said tissue collection chamber by a conduit such that a closed system is maintained, wherein said processing chamber comprises a first filter, a centrifuge, or a spinning membrane filter, or any combination thereof;

a programmable processing device capable of communication with said tissue collection chamber and said processing chamber, wherein said processing device operates a vacuum or a pump configured to use pressure to control ingress and egress of tissues through said automated cell processing unit; and

an outlet wherein said outlet is configured to allow the aseptic removal of a concentrated population comprising CD31 positive cells obtained from said processing chamber.

2. The automated cell processing unit of claim 1 , wherein said automated cell processing unit is configured to mechanically or enzymatically disaggregate said adipose tissue.

3. The automated cell processing unit of claim 1 , wherein the programmable processing device comprises software to allow for collection of a set of run data selected from the group consisting of: a lot number of a reagent, a temperature measurement, a volume measurement, a tissue volume measurement a dose of enzyme introduced into the device; an operator identity; a patient identity, and an incubation time.

4. The automated cell processing unit of claim 1 , wherein said automated cell processing unit comprises a disposable component and a hardware component.

5. The automated cell processing unit of claim 4 , wherein the disposable component comprises the collection chamber.

6. The automated cell processing unit of claim 4 , wherein the hardware component comprises a centrifuge.

7. The automated cell processing unit of claim 1 , further comprising:

a probe that can connect to at least one of said tissue collection chamber, said processing chamber, said cell concentrator, or a conduit that connects the tissue collection chamber and the cell processing chamber while maintaining a closed system.

8. The automated cell processing unit of claim 7 , wherein said probe comprises a sensor.

9. The automated cell processing unit of claim 8 , wherein said sensor is selected from the group consisting of an optical sensor, an ultrasonic sensor, and a pressure sensor.

10. The automated cell processing unit of claim 7 , wherein said sensor is configured to detect the presence of red blood cells.

11. A method of processing adipose tissue to produce a concentrated population of cells comprising CD31 positive cells, comprising

introducing adipose tissue that comprises a population of cells comprising CD31 positive cells into the automated cell processing unit of claim 1 ; and

processing said adipose tissue to obtain a concentrated population of cells comprising adipose-derived CD31-positive cells.

12. The method of claim 11 , further comprising a disaggregation step, wherein said adipose tissue is mechanically or enzymatically disaggregated.

13. The method of claim 12 , wherein said disaggregation step comprises an enzymatic digestion.

14. The method of claim 13 , wherein said enzymatic digestion comprises collagenase treatment.

15. The method of claim 13 , wherein said enzymatic digestion comprises treatment with a neutral protease.

16. The method of claim 13 , wherein said enzymatic digestion is inhibited by human serum.

17. The method of claim 11 , wherein said automated cell processing unit comprises a probe that comprises a sensor.

18. The method of claim 17 , wherein said sensor is selected from the group consisting of an optical sensor, an ultrasonic sensor, and a pressure sensor.

19. The method of claim 17 , wherein said sensor is configured to detect the presence of red blood cells in said sample.

20. The method of claim 11 , further comprising:

receiving an input from a user that identifies whether said concentrated population of cells comprising adipose-derived CD31-positive cells will be administered intravascularly, non-systemically, or both; and

determining the presence of at least one factor selected from the group consisting of adipocytes, free lipids, a proteolytic substance, a platelet aggregating substance, and an endotoxin in said concentrated population of cells comprising CD31-positive cells.

21. The method of claim 20 , wherein the presence of an endotoxin, a proteolytic enzyme, a platelet aggregating substance, or free lipids is determined when the input received from said user identifies that said concentrated population of cells comprising CD31-positive cells will be administered intravascularly.

22. The method of claim 21 , wherein said determining step is automatically performed.

23. The method of claim 21 , wherein said determining step is not automatically performed.

24. The automated cell processing unit of claim 5 , wherein said collection chamber comprises a flexible bag.

25. The automated cell processing unit of claim 1 , further comprising a support for said collection chamber, said support comprising an internal frame or an external frame.

26. The automated cell processing unit of claim 1 , wherein the collection chamber is configured to receive between 5 ml and 2 liters of adipose tissue.

27. The automated cell processing unit of claim 1 , further comprising an agitation mechanism that agitates the collection chamber.

Assignments (8)
CORRECTIVE ASSIGNMENT TO CORRECT THE CORRECT ASSIGNEE'S ADDRESS PREVIOUSLY RECORDED AT REEL: 049313 FRAME: 0434. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Aug 1, 2019
From: CYTORI THERAPEUTICS, INC.
To: LOREM VASCULAR PTE. LTD.
Reel/Frame 049942/0204 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 17, 2019
From: CYTORI THERAPEUTICS, INC.
To: LOREM VASCULAR PTE. LTD.
Reel/Frame 049313/0434 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 25, 2019
From: CYTORI THERAPEUTICS, INC.
To: LOREM VASCULAR PTE. LTD.
Reel/Frame 049651/0001 →
RELEASE OF SECURITY INTEREST Recorded Apr 25, 2019
From: OXFORD FINANCE LLC
To: CYTORI THERAPEUTICS, INC.
Reel/Frame 049011/0347 →
SECURITY INTEREST Recorded Sep 22, 2017
From: CYTORI THERAPEUTICS, INC.
To: OXFORD FINANCE LLC, AS COLLATERAL AGENT
Reel/Frame 043952/0150 →
RELEASE OF SECURITY INTEREST Recorded Jun 12, 2015
From: OXFORD FINANCE LLC
To: CYTORI THERAPEUTICS, INC.
Reel/Frame 035902/0191 →
RELEASE OF SECURITY INTEREST Recorded Jul 3, 2013
From: GENERAL ELECTRIC CAPITAL CORPORATION
To: CYTORI THERAPEUTICS, INC.
Reel/Frame 030734/0778 →
SECURITY AGREEMENT Recorded Jun 28, 2013
From: CYTORI THERAPEUTICS, INC.
To: OXFORD FINANCE LLC
Reel/Frame 030715/0625 →